Literature DB >> 17165577

[Progress in research on mechanisms of anti-rheumatoid arthritis of triptolide].

Chun-Fang Liu1, Na Lin.   

Abstract

Extracts of Tripterygium wilfordii are effective in traditional Chinese medicine for treatment of rheumatoid arthritis (RA). Triptolide, a diterpenoid triepoxide purified from TWHF, has been identified as the major component of TWHF and might account for its therapeutic effects. To make for the clinical reasonable application and further development of triptolide, in this review was introduced the recent ten-years progress in mechanisms of anti-RA of it, including immunosuppression, anti-inflammation, inducing cell apoptosis, inhibiting vascular proliferation, protecting article cartilage and gene regulation. Triptolide is a potent immunosuppressant.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17165577

Source DB:  PubMed          Journal:  Zhongguo Zhong Yao Za Zhi        ISSN: 1001-5302


  4 in total

1.  Triptolide and l-ascorbate palmitate co-loaded micelles for combination therapy of rheumatoid arthritis and side effect attenuation.

Authors:  Man Li; Guoqiang Wang; Yinyin Yan; Mengyuan Jiang; Zhirong Wang; Zhenqiang Zhang; Xiangxiang Wu; Huahui Zeng
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.819

2.  Disseminated cutaneous Kaposi sarcoma in a patient receiving triptolide/tripdiolide for rheumatoid arthritis.

Authors:  Alicja E Grzegorzewska; Dorota Frankiewicz; Danuta Bręborowicz; Irena Matławska; Wiesława Bylka
Journal:  Med Sci Monit       Date:  2012-08

3.  Antioedematous and Analgesic Properties of Fertile Fronds of Drynaria quercifolia.

Authors:  G I Anuja; P G Latha; V J Shine; S R Suja; P Shikha; K Satheesh Kumar; S Rajasekharan
Journal:  ISRN Inflamm       Date:  2014-01-20

4.  Deciphering the Active Ingredients and Molecular Mechanisms of Tripterygium hypoglaucum (Levl.) Hutch against Rheumatoid Arthritis Based on Network Pharmacology.

Authors:  Yunbin Jiang; Mei Zhong; Fei Long; Rongping Yang
Journal:  Evid Based Complement Alternat Med       Date:  2020-01-13       Impact factor: 2.629

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.